{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T10:11:38Z","timestamp":1789035098045,"version":"build-2803163510"},"reference-count":69,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.m2026.0141","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T09:27:52Z","timestamp":1789032472000},"source":"Crossref","is-referenced-by-count":0,"title":["Recommendations on switching or deprescribing hypnotic medications for insomnia"],"prefix":"10.3238","author":[{"given":"G\u00f6ran","family":"Hajak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingo","family":"Fietze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Sch\u00f6bel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Saletu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"H\u00f6gl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaroslav","family":"Winter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11437","published-online":{"date-parts":[[2026,9,18]]},"reference":[{"key":"10.3238\/arztebl.m2026.0141_ref1","doi-asserted-by":"crossref","unstructured":"L\u00e9ger D, Poursain B, Neubauer D, Uchiyama M: An international survey of sleeping problems in the general population. Curr Med Res Opin 2008; 24: 307\u201317","DOI":"10.1185\/030079907X253771"},{"key":"10.3238\/arztebl.m2026.0141_ref2","unstructured":"Riemann D, Espie CA, Altena E, et al.: The European Insomnia Guideline: An update on the diagnosis and treatment of insomnia 2023. J Sleep Res 2023; 32: e14035"},{"key":"10.3238\/arztebl.m2026.0141_ref3","doi-asserted-by":"crossref","unstructured":"Spiegelhalder K, Baum E, Becker M, et al.: Leitlinie \u201eInsomnie bei Erwachsenen\u201c \u2013 Update 2025 (AWMF-Registernummer 063\u2013003) Version 2.0. Somnologie 2025; 29: 240\u201377","DOI":"10.1007\/s11818-025-00530-6"},{"key":"10.3238\/arztebl.m2026.0141_ref4","doi-asserted-by":"crossref","unstructured":"Watson NF, Benca RM, Krystal AD, McCall WV, Neubauer DN: Alliance for sleep clinical practice guideline on switching or deprescribing hypnotic medications for insomnia. J Clin Med 2023; 12: 2493","DOI":"10.3390\/jcm12072493"},{"key":"10.3238\/arztebl.m2026.0141_ref5","doi-asserted-by":"crossref","unstructured":"Palagini L, Brugnoli R, Dell\u2018 Osso BM, et al.: Clinical practice guidelines for switching or deprescribing hypnotic medications for chronic insomnia: Results of European neuropsychopharmacology and sleep expert\u2018s consensus group. Sleep Med 2025; 128: 117\u201326","DOI":"10.1016\/j.sleep.2025.01.033"},{"key":"10.3238\/arztebl.m2026.0141_ref6","doi-asserted-by":"crossref","unstructured":"Zhang Y, Ren R, Yang L, et al.: Comparative efficacy and acceptability of psychotherapies, pharmacotherapies, and their combination for the treatment of adult insomnia: A systematic review and network meta-analysis. Sleep Med Rev 2022; 65: 101687","DOI":"10.1016\/j.smrv.2022.101687"},{"key":"10.3238\/arztebl.m2026.0141_ref7","unstructured":"Pottie K, Thompson W, Davies S, et al.: Deprescribing benzodiazepine receptor agonists: Evidence-based clinical practice guideline. Can Fam Physician 2018; 64: 339\u201351"},{"key":"10.3238\/arztebl.m2026.0141_ref8","doi-asserted-by":"crossref","unstructured":"Vinkers CH, Kupka RW, Penninx BW, et al.: Discontinuation of psychotropic medication: A synthesis of evidence across medication classes. Mol Psychiatry 2024; 29: 2575\u201386","DOI":"10.1038\/s41380-024-02445-4"},{"key":"10.3238\/arztebl.m2026.0141_ref9","doi-asserted-by":"crossref","unstructured":"R\u00f6sner S, Englbrecht C, Wehrle R, Hajak G, Soyka M: Eszopiclone for insomnia. Cochrane Database Syst Rev 2018; 10: CD010703","DOI":"10.1002\/14651858.CD010703.pub2"},{"key":"10.3238\/arztebl.m2026.0141_ref10","doi-asserted-by":"crossref","unstructured":"Winter Y, Arnaldi D: Daridorexant: Exploring its role in the treatment of insomnia disorder. Expert Rev Neurother 2026; 26: 325\u201340","DOI":"10.1080\/14737175.2026.2639557"},{"key":"10.3238\/arztebl.m2026.0141_ref11","doi-asserted-by":"crossref","unstructured":"Kishi T, Ikuta T, Citrome L, et al.: Comparative efficacy and safety of daridorexant, lemborexant, and suvorexant for insomnia: A systematic review and network meta-analysis. Transl Psychiatry 2025; 15: 211","DOI":"10.1038\/s41398-025-03439-8"},{"key":"10.3238\/arztebl.m2026.0141_ref12","doi-asserted-by":"crossref","unstructured":"Mignot E, Mayleben D, Fietze I, et al.: Safety and efficacy of daridorexant in patients with insomnia disorder: Results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials. Lancet Neurol 2022; 21: 125\u201339","DOI":"10.1016\/S1474-4422(21)00436-1"},{"key":"10.3238\/arztebl.m2026.0141_ref13","doi-asserted-by":"crossref","unstructured":"Kunz D, Dauvilliers Y, Benes H, et al.: Long-term safety and tolerability of daridorexant in patients with insomnia disorder. CNS Drugs 2023; 37: 93\u2013106","DOI":"10.1007\/s40263-022-00980-8"},{"key":"10.3238\/arztebl.m2026.0141_ref14","doi-asserted-by":"crossref","unstructured":"Lemoine P, Garfinkel D, Laudon M, Nir T, Zisapel N: Prolonged-release melatonin for insomnia\u2014an open-label long-term study of efficacy, safety, and withdrawal. Ther Clin Risk Manag 2011; 7: 301\u201311","DOI":"10.2147\/TCRM.S23036"},{"key":"10.3238\/arztebl.m2026.0141_ref15","doi-asserted-by":"crossref","unstructured":"Hajak G, Lemme K, Zisapel N: Lasting treatment effects in a postmarketing surveillance study of prolonged-release melatonin. Int Clin Psychopharmacol 2015; 30: 36\u201342","DOI":"10.1097\/YIC.0000000000000046"},{"key":"10.3238\/arztebl.m2026.0141_ref16","doi-asserted-by":"crossref","unstructured":"Kalfas M, Tsapekos D, Butler M, et al.: Incidence and nature of antidepressant discontinuation symptoms: A systematic review and meta-analysis. JAMA Psychiatry 2025; 82: 896\u2013904","DOI":"10.1001\/jamapsychiatry.2025.1362"},{"key":"10.3238\/arztebl.m2026.0141_ref17","doi-asserted-by":"crossref","unstructured":"Quilichini JB, Revet A, Garcia P, et al.: Comparative effects of 15 antidepressants on the risk of withdrawal syndrome: A real-world study using the WHO pharmacovigilance database. J Affect Disord 2022; 297: 189\u201393","DOI":"10.1016\/j.jad.2021.10.041"},{"key":"10.3238\/arztebl.m2026.0141_ref18","doi-asserted-by":"crossref","unstructured":"Gastaldon C, Schoretsanitis G, Arzenton E, et al.: Withdrawal syndrome following discontinuation of 28 antidepressants: Pharmacovigilance analysis of 31,688 reports from the WHO spontaneous reporting database. Drug Saf 2022; 45: 1539\u201349","DOI":"10.1007\/s40264-022-01246-4"},{"key":"10.3238\/arztebl.m2026.0141_ref19","doi-asserted-by":"crossref","unstructured":"Riemann D, Voderholzer U, Cohrs S, et al.: Trimipramine in primary insomnia: Results of a polysomnographic double-blind controlled study. Pharmacopsychiatry 2002; 35: 165\u201374","DOI":"10.1055\/s-2002-34119"},{"key":"10.3238\/arztebl.m2026.0141_ref20","doi-asserted-by":"crossref","unstructured":"Hajak G, Rodenbeck A, Voderholzer U, et al.: Doxepin in the treatment of primary insomnia: A placebo-controlled, double-blind, polysomnographic study. J Clin Psychiatry 2001; 62: 453\u201363","DOI":"10.4088\/JCP.v62n0609"},{"key":"10.3238\/arztebl.m2026.0141_ref21","doi-asserted-by":"crossref","unstructured":"Storck W, de Laportali\u00e8re TT, Yrondi A, Javelot H, Berna F, Montastruc F: Withdrawal syndrome after antipsychotics discontinuation: An analysis of the WHO database of spontaneous reports (Vigibase) between 2000 and 2022. Psychopharmacology (Berl) 2024; 241: 1205\u201312","DOI":"10.1007\/s00213-024-06554-4"},{"key":"10.3238\/arztebl.m2026.0141_ref22","doi-asserted-by":"crossref","unstructured":"Papanna B, Lazzari C, Kulkarni K, Perumal S, Nusair A: Pregabalin abuse and dependence during insomnia and protocol for short-term withdrawal management with diazepam: Examples from case reports. Sleep Sci 2021; 14: 193\u20137","DOI":"10.5935\/1984-0063.20200129"},{"key":"10.3238\/arztebl.m2026.0141_ref23","doi-asserted-by":"crossref","unstructured":"Hosseini A, Mobasheri L, Rakhshandeh H, Rahimi VB, Najafi Z, Askari VR: Edible herbal medicines as an alternative to common medication for sleep disorders: A review article. Curr Neuropharmacol 2024; 22: 1205\u201332","DOI":"10.2174\/1570159X21666230621143944"},{"key":"10.3238\/arztebl.m2026.0141_ref24","doi-asserted-by":"crossref","unstructured":"Burke H, Jiang S, Chatham P, Stern TA: Delirium after withdrawal from valerian root: A case report. Psychosomatics 2020; 61: 787\u201390","DOI":"10.1016\/j.psym.2020.05.003"},{"key":"10.3238\/arztebl.m2026.0141_ref25","unstructured":"Winter Y. (Hrsg.). Kompendium Schlafmedizin. F\u00fcr Ausbildung, Klinik und Praxis. Landsberg: ecomed Medizin; 2026."},{"key":"10.3238\/arztebl.m2026.0141_ref26","doi-asserted-by":"crossref","unstructured":"Olderbak S, Hollweck R, Krowartz EM, M\u00f6ckl J, Hoch E: Psychoactive substance use in Germany: Findings from the Epidemiological Survey of Substance Abuse (ESA) in 2024. Dtsch Arztebl Int 2025; 122: 625\u201331","DOI":"10.3238\/arztebl.m2025.0157"},{"key":"10.3238\/arztebl.m2026.0141_ref27","doi-asserted-by":"crossref","unstructured":"Morin CM, Jarrin DC: Epidemiology of insomnia: Prevalence, course, risk factors, and public health burden. Sleep Med Clin 2022; 17: 173\u201391","DOI":"10.1016\/j.jsmc.2022.03.003"},{"key":"10.3238\/arztebl.m2026.0141_ref28","unstructured":"Substance Abuse and Mental Health Services Administration. 2023 NSDUH annual national report. July 30, 2024. www.samhsa.gov\/data\/report\/2023-nsduh-annual-national-report (last accessed on 15 May 2026)."},{"key":"10.3238\/arztebl.m2026.0141_ref29","doi-asserted-by":"crossref","unstructured":"Snyder H, Streem D, Anand A, Viguera AC: When risks outweigh benefits: A review of the guideline on benzodiazepine tapering. Cleve Clin J Med 2026; 93: 347\u201352","DOI":"10.3949\/ccjm.93a.25102"},{"key":"10.3238\/arztebl.m2026.0141_ref30","doi-asserted-by":"crossref","unstructured":"Park KM, Kim TH, Kim WJ, An SK, Namkoong K, Lee E: Cognitive behavioral therapy for insomnia reduces hypnotic prescriptions. Psychiatry Investig 2018; 15: 499\u2013504","DOI":"10.30773\/pi.2017.11.20"},{"key":"10.3238\/arztebl.m2026.0141_ref31","doi-asserted-by":"crossref","unstructured":"Hajak G, Bandelow B, Zulley J, Pittrow D: \u201eAs needed\u201c pharmacotherapy combined with stimulus control treatment in chronic insomnia\u2014assessment of a novel intervention strategy in a primary care setting. Ann Clin Psychiatry 2002; 14: 1\u20137","DOI":"10.3109\/10401230209147392"},{"key":"10.3238\/arztebl.m2026.0141_ref32","doi-asserted-by":"crossref","unstructured":"Jobert A, Laforgue EJ, Grall-Bronnec M, et al.: Benzodiazepine withdrawal in older people: What is the prevalence, what are the signs, and which patients? Eur J Clin Pharm 2021; 77: 171\u20137","DOI":"10.1007\/s00228-020-03007-7"},{"key":"10.3238\/arztebl.m2026.0141_ref33","doi-asserted-by":"crossref","unstructured":"Kales A, Manfredi RL, Vgontzas AN, Bixler EO, Vela-Bueno A, Fee EC: Rebound insomnia after only brief and intermittent use of rapidly eliminated benzodiazepines. Clin Pharmacol Ther 1991; 49: 468\u201376","DOI":"10.1038\/clpt.1991.55"},{"key":"10.3238\/arztebl.m2026.0141_ref34","doi-asserted-by":"crossref","unstructured":"Al-Soleiti M, Park JH, Kummerlowe MN, et al.: Clinical characteristics and treatment of benzodiazepine withdrawal delirium in adults: An iIllustrative case and systematic review of published cases. J Acad Consult Liaison Psychiatry 2026: S2667\u20132960(26)00055\u20138","DOI":"10.1016\/j.jaclp.2026.06.001"},{"key":"10.3238\/arztebl.m2026.0141_ref35","doi-asserted-by":"crossref","unstructured":"Dixon CL, Harrison NL, Lynch JW, Keramidas A: Zolpidem and eszopiclone prime α1β2γ2 GABAA receptors for longer duration of activity. Br J Pharmacol 2015; 172: 3522\u201336","DOI":"10.1111\/bph.13142"},{"key":"10.3238\/arztebl.m2026.0141_ref36","doi-asserted-by":"crossref","unstructured":"Pollmann AS, Murphy AL, Bergman JC, Gardner DM: Deprescribing benzodiazepines and Z-drugs in community-dwelling adults: A scoping review. BMC Pharmacol Toxicol 2015; 16: 19","DOI":"10.1186\/s40360-015-0019-8"},{"key":"10.3238\/arztebl.m2026.0141_ref37","doi-asserted-by":"crossref","unstructured":"Green AR, Aschmann H, Boyd CM, Schoenborn N: Assessment of patient-preferred language to achieve goal-aligned deprescribing in older adults. JAMA Netw Open 2021; 4: e212633","DOI":"10.1001\/jamanetworkopen.2021.2633"},{"key":"10.3238\/arztebl.m2026.0141_ref38","doi-asserted-by":"crossref","unstructured":"Kuntz JL, Kouch L, Christian D, Hu W, Peterson PL: Patient education and pharmacist consultation influence on nonbenzodiazepine sedative medication deprescribing success for older adults. Perm J 2019; 23: 18\u2013161","DOI":"10.7812\/TPP\/18-161"},{"key":"10.3238\/arztebl.m2026.0141_ref39","doi-asserted-by":"crossref","unstructured":"Freitas C, Khanal S, Landsberg D, Kaul V: An alternative cause of encephalopathy: Valerian root overdose. Cureus 2021; 13: e17759","DOI":"10.7759\/cureus.17759"},{"key":"10.3238\/arztebl.m2026.0141_ref40","doi-asserted-by":"crossref","unstructured":"Markota M, Rummans TA, Bostwick JM, Lapid MI: Benzodiazepine use in older adults: Dangers, management, and alternative therapies. Mayo Clin Proc 2016; 91: 1632\u20139","DOI":"10.1016\/j.mayocp.2016.07.024"},{"key":"10.3238\/arztebl.m2026.0141_ref41","doi-asserted-by":"crossref","unstructured":"Riemann D, Baglioni C, Nissen C, et al.: Risks associated with benzodiazepine long-term use in chronic insomnia: A systematic review and (Network) meta-analysis. J Sleep Res 2026: e70352. doi: 10.1111\/jsr.70352. Online ahead of print","DOI":"10.1111\/jsr.70352"},{"key":"10.3238\/arztebl.m2026.0141_ref42","doi-asserted-by":"crossref","unstructured":"Savaskan E: [Benzodiazepine dependency in the elderly: How to deal with it]. Praxis (Bern 1994) 2016; 105: 637\u201341","DOI":"10.1024\/1661-8157\/a002363"},{"key":"10.3238\/arztebl.m2026.0141_ref43","doi-asserted-by":"crossref","unstructured":"Taylor HL, Rybarczyk BD, Nay W, Leszczyszyn D: Effectiveness of a CBT intervention for persistent insomnia and hypnotic dependency in an outpatient psychiatry clinic. J Clin Psychol 2015; 71: 666\u201383","DOI":"10.1002\/jclp.22186"},{"key":"10.3238\/arztebl.m2026.0141_ref44","doi-asserted-by":"crossref","unstructured":"Hatano M, Kamei H, Inagaki R, et al.: Assessment of switching to suvorexant versus the use of add-on suvorexant in combination with benzodiazepine receptor agonists in insomnia patients: A retrospective study. Clin Psychopharmacol Neurosci 2018; 16: 184\u20139","DOI":"10.9758\/cpn.2018.16.2.184"},{"key":"10.3238\/arztebl.m2026.0141_ref45","doi-asserted-by":"crossref","unstructured":"Suzuki H, Hibino H: Characteristics of patients who were able to switch from benzodiazepine hypnotics to lemborexant. SAGE Open Med 2021; 9: 20503121211037903","DOI":"10.1177\/20503121211037903"},{"key":"10.3238\/arztebl.m2026.0141_ref46","doi-asserted-by":"crossref","unstructured":"An JH, Park MJ, Fava M, et al.: Comparisons between successful versus unsuccessful switches from benzodiazepines or zolpidem (z-drug) to controlled-release melatonin in patients with major depressive disorder and insomnia. Front Psychiatry 2020; 11: 444","DOI":"10.3389\/fpsyt.2020.00444"},{"key":"10.3238\/arztebl.m2026.0141_ref47","doi-asserted-by":"crossref","unstructured":"Pat-Horenczyk R, Hacohen D, Herer P, Lavie P: The effects of substituting zopiclone in withdrawal from chronic use of benzodiazepine hypnotics. Psychopharmacology (Berl.) 1998; 140: 450\u20137","DOI":"10.1007\/s002130050789"},{"key":"10.3238\/arztebl.m2026.0141_ref48","doi-asserted-by":"crossref","unstructured":"Murphy SM, Tyrer P: A double-blind comparison of the effects of gradual withdrawal of lorazepam, diazepam and bromazepam in benzodiazepine dependence. Br J Psychiatry 1991; 158: 511\u20136","DOI":"10.1192\/bjp.158.4.511"},{"key":"10.3238\/arztebl.m2026.0141_ref49","doi-asserted-by":"crossref","unstructured":"Busto U, Sellers EM, Naranjo CA, Cappell H, Sanchez-Craig M, Sykora K: Withdrawal reaction after long-term therapeutic use of benzodiazepines. N Engl J Med 1986; 315: 854\u20139","DOI":"10.1056\/NEJM198610023151403"},{"key":"10.3238\/arztebl.m2026.0141_ref50","unstructured":"Shapiro CM, Devins GM, Hussain MRG: Withdrawal from benzodiazepines by initially switching to zopiclone. Br J Psychiatry 1990; 156: 568\u201375."},{"key":"10.3238\/arztebl.m2026.0141_ref51","doi-asserted-by":"crossref","unstructured":"Boyle J, Groeger JA, Paska W, et al.: A method to assess the dissipation of the residual effects of hypnotics: Eszopiclone versus zopiclone. J Clin Psychopharmacol 2012; 32: 704\u20139","DOI":"10.1097\/JCP.0b013e3182664eec"},{"key":"10.3238\/arztebl.m2026.0141_ref52","doi-asserted-by":"crossref","unstructured":"Ozone M, Hirota S, Ariyoshi Y, et al.: Efficacy and safety of transitioning to lemborexant from Z-drug, suvorexant, and ramelteon in Japanese insomnia patients: An open-label, multicenter study. Adv Ther 2024; 41: 1728\u201345","DOI":"10.1007\/s12325-024-02811-2"},{"key":"10.3238\/arztebl.m2026.0141_ref53","unstructured":"Krystal AD, Lankford A, Durrence HH, et al.: Efficacy and safety of doxepin 3 and 6 mg in a 35-day sleep laboratory trial in adults with chronic primary insomnia. Sleep 2011; 34: 1433\u201342."},{"key":"10.3238\/arztebl.m2026.0141_ref54","unstructured":"Ferguson JM, Mendels J, Manowitz NR, Prothiaden Collaborative Study Group: Dothiepin versus doxepin in major depression: Results of a multicenter, placebo-controlled trial. J Clin Psychiatry 1994; 55: 258\u201363."},{"key":"10.3238\/arztebl.m2026.0141_ref55","unstructured":"Mayer G, Wang-Weigand S, Roth-Schechter B, Lehmann R, Staner C, Partinen M: Efficacy and safety of 6-month nightly ramelteon administration in adults with chronic primary insomnia. Sleep 2009; 32: 351\u201360"},{"key":"10.3238\/arztebl.m2026.0141_ref56","doi-asserted-by":"crossref","unstructured":"Uchiyama M, Hamamura M, Kuwano T, et al.: Long- term safety and efficacy of ramelteon in Japanese patients with chronic insomnia. Sleep Med 2011; 12: 127\u201333","DOI":"10.1016\/j.sleep.2010.10.006"},{"key":"10.3238\/arztebl.m2026.0141_ref57","doi-asserted-by":"crossref","unstructured":"Zammit G, Erman M, Wang-Weigand S, Sainati S, Zhang J, Roth T: Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia. J Clin Sleep Med 2007; 3: 495\u2013504","DOI":"10.5664\/jcsm.26914"},{"key":"10.3238\/arztebl.m2026.0141_ref58","doi-asserted-by":"crossref","unstructured":"Lemoine P, Garfinkel D, Laudon M, Nir T, Zisapel N: Prolonged-release melatonin for insomnia\u2014an open-label long-term study of efficacy, safety, and withdrawal. Ther Clin Risk Manag 2011; 7: 301\u201311","DOI":"10.2147\/TCRM.S23036"},{"key":"10.3238\/arztebl.m2026.0141_ref59","unstructured":"Oxford Centre for Evidence-Based Medicine: Levels of Evidence (March 2009) www.cebm.ox.ac.uk\/resources\/levels-of-evidence\/oxford-centre-for-evidence-based-medicine-levels-of-evidence-march-2009 (last accessed on 15 December 2025)."},{"key":"10.3238\/arztebl.m2026.0141_ref60","doi-asserted-by":"crossref","unstructured":"Tachibana M, Kanahara N, Oda Y, Hasegawa T, Kimura A, Iyo M: A retrospective clinical practice study comparing the usefulness of dual-orexin receptor antagonists and a melatonin receptor agonist in patients switching from long-term benzodiazepine receptor agonists. J Clin Sleep Med 2024; 20: 603\u201313","DOI":"10.5664\/jcsm.10946"},{"key":"10.3238\/arztebl.m2026.0141_ref61","doi-asserted-by":"crossref","unstructured":"Takaesu Y, Suzuki M, Moline M, et al.: Effect of discontinuation of lemborexant following long-term treatment of insomnia disorder: Secondary analysis of a randomized clinical trial. Clin Transl Sci 2023; 16: 581\u201392","DOI":"10.1111\/cts.13470"},{"key":"10.3238\/arztebl.m2026.0141_ref62","doi-asserted-by":"crossref","unstructured":"Michelson D, Snyder E, Paradis E, et al.: Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: A phase 3 randomised, double-blind, placebo-controlled trial. Lancet Neurol 2014; 13: 461\u201371","DOI":"10.1016\/S1474-4422(14)70053-5"},{"key":"10.3238\/arztebl.m2026.0141_ref63","doi-asserted-by":"crossref","unstructured":"K\u00e4rpp\u00e4 M, Yardley J, Pinner K, et al.: Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: Results from the phase 3 randomized clinical trial SUNRISE 2. Sleep 2020; 43: zsaa123","DOI":"10.1093\/sleep\/zsaa123"},{"key":"10.3238\/arztebl.m2026.0141_ref64","doi-asserted-by":"crossref","unstructured":"Lindahl O, Lindwall L: Double blind study of a valerian preparation. Pharmacol Biochem Behav 1989; 32: 1065\u20136","DOI":"10.1016\/0091-3057(89)90082-8"},{"key":"10.3238\/arztebl.m2026.0141_ref65","doi-asserted-by":"crossref","unstructured":"Donath F, Quispe S, Diefenbach K, Maurer A, Fietze I, Roots I: Critical evaluation of the effect of valerian extract on sleep structure and sleep quality. Pharmacopsychiatry 2000; 33: 47\u201353","DOI":"10.1055\/s-2000-7972"},{"key":"10.3238\/arztebl.m2026.0141_ref66","doi-asserted-by":"crossref","unstructured":"Stevinson C, Ernst E: Valerian for insomnia: A systematic review of randomized clinical trials. Sleep Med 2000; 1: 91\u20139","DOI":"10.1016\/S1389-9457(99)00015-5"},{"key":"10.3238\/arztebl.m2026.0141_ref67","doi-asserted-by":"crossref","unstructured":"Monti JM, Attali P, Monti D, Zipfel A, de la Giclais B, Morselli PL: Zolpidem and rebound insomnia\u2014a double-blind, controlled polysomnographic study in chronic insomniac patients. Pharmacopsychiatry 1994; 27: 166\u201375","DOI":"10.1055\/s-2007-1014298"},{"key":"10.3238\/arztebl.m2026.0141_ref68","doi-asserted-by":"crossref","unstructured":"Lemoine P, Allain H, Janus C, Sutet P: Gradual withdrawal of zopiclone (7.5 mg) and zolpidem (10 mg) in insomniacs treated for at least 3 months. Eur Psychiatry 1995; 10 (Suppl. 3): 161s\u20135s","DOI":"10.1016\/0924-9338(96)80098-8"},{"key":"10.3238\/arztebl.m2026.0141_ref69","doi-asserted-by":"crossref","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71","DOI":"10.1136\/bmj.n71"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2026.0141","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T09:28:28Z","timestamp":1789032508000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2026.0141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":69,"URL":"https:\/\/doi.org\/10.3238\/arztebl.m2026.0141","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,18]]}}}